Glaukos
GKOSGlaukos is an ophthalmic pharmaceutical and medical technology company that pioneered Micro-Invasive Glaucoma Surgery (MIGS) to treat chronic eye diseases.
Earnings
Next report
Date not yet announcedValuation & ratios
Segments
Competitors
By market cap
By revenue growth
Profile
Glaukos is an ophthalmic pharmaceutical and medical technology company that pioneered Micro-Invasive Glaucoma Surgery (MIGS) to treat chronic eye diseases. The company develops and commercializes a diverse portfolio of dropless therapies, including micro-scale surgical devices, sustained-release pharmaceutical implants, and bio-activated therapies for glaucoma, corneal disorders, and retinal diseases.
Competitive position
A market leader in the MIGS category that is transitioning into a hybrid pharmaceutical and device company with first-of-its-kind sustained-release implants.
GeographiesUnited States, European Union, Japan, Australia, Canada, Brazil, United Kingdom
Customer segmentsSurgical centers, Hospitals, Specialized medical practices
Business modelProduct manufacturing and sales, Research and development, Direct-to-provider sales
SuppliersThird-party pharmaceutical manufacturers, Specialized component suppliers, Raw material providers for micro-scale devices
CustomersOphthalmic surgeons, Ambulatory Surgery Centers (ASCs), Hospitals, Independent distribution partners
CountryUnited States of America
Listed2015
Employees907.0
CEOThomas William Burns
SectorHealthcare
IndustryMedical - Devices
Websiteglaukos.com
FilingsSEC EDGAR
Questions, answered.
- What is Glaukos's market cap?
- Glaukos (GKOS) has a market capitalization of $8.9B and trades on NYSE.
- What is Glaukos's revenue and profitability?
- Glaukos generated $612.8M in trailing twelve-month revenue with a net loss of $188.0M, representing a net margin of -30.7%. Gross margin stands at 61.0%, with free cash flow of -$37.6M. These figures are based on the Q2 2026 filing.
- Who are Glaukos's competitors?
- Glaukos's key competitors include Regeneron Pharmaceuticals, Inc., Bausch + Lomb, Sight Sciences, and others. These companies compete in similar markets and product categories.
- Who does Glaukos partner with?
- Glaukos's notable partners include Santen Pharmaceutical Co., Ltd., Attillaps Holdings, Inc., Ripple Therapeutics Corporation.
- What subsidiaries does Glaukos have?
- Glaukos's subsidiaries include Mobius Therapeutics, LLC.
- Where is Glaukos headquartered?
- Glaukos is headquartered in United States of America and employs approximately 907 people. It has been publicly traded since 2015.
